key: cord-1040554-tax79scn
authors: Park, Moon Ho; Kwon, Do Young
title: A retrospective review of memantine use and COVID‐19‐associated mortality from a national database
date: 2020-07-14
journal: J Med Virol
DOI: 10.1002/jmv.26266
sha: 41e1624ba8d4daf7ab960631adebc7b85e6859b9
doc_id: 1040554
cord_uid: tax79scn

We read with interest the recent papers by Brenner and Cimolai regarding the therapeutic potential of memantine for coronavirus disease (COVID-19). In this retrospective, we investigated the relationship between treatment with memantine and COVID-19-associated mortality in 5,726 patients with COVID-19, of whom 140 had died. Our analysis revealed no association between memantine treatment and mortality in patients with COVID-19. However, we must explore all feasible options for preventing and treating COVID-19 due to the current lack of licensed vaccines or therapeutics for the disease. This article is protected by copyright. All rights reserved.

A retrospective review of memantine use and COVID-19-associated mortality from a national database To the Editor,

We read with interest the papers by Brenner 1 and Cimolai 2 regarding the therapeutic potential of memantine for coronavirus disease 2019 . Memantine, an adamantane derivative and an N-methyl-D-aspartate (NMDA) receptor antagonist that reduces glutamate toxicity by decreasing the prolonged Ca 2+ influx in neurons, is used for treating Alzheimer's disease.

Angiotensin-converting enzyme 2 (ACE2), a cell surface receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is widely distributed in multiple organs, including the nose, lungs, kidneys, liver, blood vessels, immune system, and brain. Memantine may be a candidate drug for COVID-19 treatment as it interferes with NMDA activity and inhibits excess glutamate release in the medulla, which is a potential neurotoxic effect resulting from ACE2 depletion and which contributes to the development of acute respiratory distress syndrome via activating the sympathetic nervous system, thereby leading to increased blood pressure, systemic vasoconstriction, and pulmonary capillary leakage. 1,2 Memantine also directly inhibits viral replication through potential interaction with viral E protein and lysosomal function. 3 A recent study reported that 22 patients with the neurologic disorder who were diagnosed with polymerase chain reaction-confirmed SARS-CoV-2 infection and treated with memantine or related adamantanes did not develop clinical symptoms of COVID-19. 4 Our observations revealed no statistically significant relationship between COVID-19-associated mortality and ongoing treatment with memantine after adjustment for clinically relevant potential confounders of age, sex, and/or comorbidities. This result was consistently observed both in the overall analysis of all patients with COVID-19 and in the subgroup analysis that was limited to patients with dementia ( Figure 1 ).

Our results should be interpreted with caution given the disadvantage associated with retrospective analyses and reliability of data. However, memantine is typically prescribed to older patients, F I G U R E 1 Likelihood of mortality in patients with confirmed coronavirus disease 2019 according to treatment with memantine. Univariate and multivariable logistic regressions were used to estimate odds ratio and 95% confidence intervals (CIs). Univariate logistic regression did not adjust any confounder. Multivariable logistic regression model 1 adjusted for age and sex. Multivariable logistic regression model 2 adjusted for age, sex, and comorbidities (hypertension, heart failure, chronic kidney disease, chronic lung disease, diabetes mellitus, dyslipidemia, cancer, stroke, Parkinson's disease, epilepsy, and dementia) at admission. The analysis variables for this study were presented in Supporting Information Table

The potential of memantine and related adamantanes such as amantadine, to reduce the neurotoxic effects of COVID-19, including ARDS and to reduce viral replication through lysosomal effects

Potentially repurposing adamantanes for COVID-19

Evidence for lysosomotropism of memantine in cultured human cells: cellular kinetics and effects of memantine on phospholipid content and composition, membrane fluidity and beta-adrenergic transmission

Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment

World Health Organization